


RESEARCH ARTICLE

Engineered romidepsin biosynthetic pathways in *Escherichia coli* Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy

Chenghao Ma¹, Geng Li¹, Tao Sun¹, Ximi Tang¹, Tong Qiu^{1,2}, Jingwen Song^{1,2}, Hailong Wang^{1*}, Youming Zhang^{1,3*}, Tianyu Jiang^{1*}

1 State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Helmholtz International Lab for Anti-Infectives, Shandong University–Helmholtz Institute of Biotechnology, Shandong University, Qingdao, China, **2** School of Life Sciences, Shandong University, Qingdao, China, **3** Shenzhen Key Laboratory of Genome Manipulation and Biosynthesis, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China

* wanghailong@sdu.edu.cn (HW); zhangyouming@sdu.edu.cn (YZ); tianyujiang@sdu.edu.cn (TJ)



OPEN ACCESS

Citation: Ma C, Li G, Sun T, Tang X, Qiu T, Song J, et al. (2026) Engineered romidepsin biosynthetic pathways in *Escherichia coli* Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy. PLoS Biol 24(3): e3003657. <https://doi.org/10.1371/journal.pbio.3003657>

Academic Editor: Matthew Wook Chang, National University of Singapore, SINGAPORE

Received: March 10, 2025

Accepted: February 2, 2026

Published: March 17, 2026

Copyright: © 2026 Ma et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data availability statement: All relevant data are within the paper and its [Supporting information](https://figshare.com/s/340f560874499f66444e) files. The raw data for figures is listed in <https://figshare.com/s/340f560874499f66444e>. The mass spectrometry proteomics data have been deposited to the ProteomeXchange

Abstract

The probiotic strain *Escherichia coli* Nissle 1917 (EcN), a potential member of tumor-targeting bacteria, shows great promise for cancer treatment. By leveraging engineered EcN, we can design a bacteria-assisted, tumor-targeted therapy for the biosynthesis and targeted delivery of small-molecule anticancer agents. In this study, we aimed to use EcN as a base for synthesizing Romidepsin (FK228), an FDA-approved drug originally made by *Chromobacterium violaceum* No. 96. Through gene cluster reconstruction, promoter optimization, and genome modification, we created FK228-producing strains to boost anticancer efficacy. The engineered strain achieved a maximum in vitro yield of 1.5 mg/L. In 4T1 tumor-bearing BALB/c mouse xenograft models, six recombinant strains outperformed the wild-type EcN. Proteome showed that inflammatory response induced by EcN combined with intratumoral FK228 production improved treatment results. Also, targeted synthesis reduced FK228's cardiotoxicity and mortality. Engineered EcN enables drug biosynthesis and precise delivery, offering powerful anticancer activity.

Introduction

Over the last few decades, the renaissance of bacterium-mediated cancer therapy based on bacteria with the ability to specifically colonize in tumors has been witnessed with the progress of synthetic biology [1]. The tumor-targeting bacteria used in this field include *Salmonella*, *Listeria*, *Bifidobacterium*, *Escherichia coli* [2–5]. Some of these bacteria themselves can kill cancer cells, and some can be genetically engineered to express therapeutic molecules such as anticancer peptides [2,6], checkpoint inhibitors [7], neoantigens [4], small molecules [8–10].

Consortium via the PRIDE partner repository with the dataset identifier PXD073783.

Funding: This study was supported by the National Natural Science Foundation of China (32201245 to T.J., 32122049 to Y.Z., 32161133013 to Y.Z.), the Fundamental Research Funds of Shandong University (2023QNTD001 to H.W.), the Future Plan for Young Scholars of Shandong University (T.J.), the Fund for Distinguished Young Scholars of SDU (H.W.), the Natural Science Foundation of Shandong Province (ZR2022JQ11 to H.W.), the SKLMT Frontiers and Challenges Project (SKLMTFCP-2023-05 to Y.Z.), the Shenzhen Science and Technology Program (ZDSYS20220303153551001 to Y.Z.), the 111 Project (B16030), and the Intestinal Microbiology Research Fund of the Institute of Microbiology Technology (Project NO. cdwswjj-2025-02 to T.J.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: AT, acyltransferase; CFU, colony-forming units; EcN, *Escherichia coli* Nissle 1917; FBS, Fetal Bovine Serum; GO, Gene Ontology; LB, Luria-Bertani; NRPSs, non-ribosomal peptide synthetases; PKSs, polyketide synthetases; SEM, Standard error of the mean; FC, Fold change.

Probiotic *Escherichia coli* Nissle 1917 (EcN) exhibits the capacity to both accumulate and proliferate within solid tumors, which makes it a highly promising live vector for application in bacterial cancer therapy [11]. In recent years, EcN has been reprogrammed to produce and deliver peptides [12] or chemical coupling with small molecule drugs [13,14] to realize anticancer therapy. Roger Geiger and colleagues reprogrammed EcN to have the ability to convert L-arginine from ammonia in tumor microenvironment, which assists PD-L1 antibody to enhance tumor immunotherapy [9]. Tal Danino and colleagues developed an engineered EcN to express checkpoint blockade nanobodies [7] or nanobody inhibitors [6] so as to induce antitumor immunity.

Besides, a few reports indicated that EcN has been engineered to heterogeneously synthesize small molecules to improve bacterial anticancer activities. For example, EcN has been genetically engineered to synthesize cyclic-di-AMP to disturb the STING pathway for antitumor immunity [8].

Since a diverse range of clinical antitumor drugs originate from microbial metabolites [15], some tumor-targeting bacteria possess the potential to achieve heterogeneous biosynthesis of therapeutic agents originating from microorganisms and transport them to the targeted tumors. EcN has been genetically engineered to heterogeneously express cytotoxic compounds glidobactin, luminmide, and colibactin [9]. Thus, a bacteria-assisted tumor-targeted therapy can be established by using engineered EcN for biosynthesis and delivery of small-molecule anticancer drugs.

Romidepsin (FK228) is an FDA-approved drug for cancer chemotherapy naturally produced by *Chromobacterium violaceum* strain 968. As a potent histone deacetylase inhibitor (HDACi), FK228 has been used for the treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma [16]. Besides, FK228 has been used for the treatment of solid tumors such as breast cancer and pancreatic cancer in preclinical studies [16,17]. It is anticipated that the antitumor activity of FK228 in the treatment of solid tumors will be enhanced provided that its tumor-targeting ability has been strengthened. FK228 is a depsipeptide biosynthesized by nonribosomal peptide synthetases (NRPSs) and type I polyketide synthetases (PKSs). The gene cluster of FK228 is about 36kb, including 3 NRPS modules, 2 PKS modules, and other related genes. A hybrid nonribosomal peptide synthetase-polyketide synthase pathway, which is involved in FK228 biosynthesis within *C. violaceum*, has been proposed and its characteristics have been determined [18]. Recently, efforts have been made to improve the yield of FK228 in *Chromobacterium* and *Burkholderia* chassis for industrial production [19–21].

Considering that EcN is a probiotic bacterial strain with a propensity to colonize tumors rather than other tissues or organs, it was selected as a secure chassis in our study. Additionally, as FK228 plays a role in cancer chemotherapy and its biosynthesis pathway is clear, we aimed to genomically reconstruct the gene clusters of FK228 and introduce the optimized biosynthetic pathway into the EcN, so as to achieve the biosynthesis and tumor-targeting delivery of FK228 and attain anticancer activity (Fig 1).




Fig 1. The strategy for introducing the optimized biosynthetic pathway into the EcN to realize the biosynthesis and tumor-targeting delivery of FK228 to achieve anticancer activity.

<https://doi.org/10.1371/journal.pbio.3003657.g001>

Results and discussions

Heterogeneous biosynthesis of FK228 in EcN

A previous study demonstrated that a 12-gene dep gene cluster encodes a hybrid modular NRPS-PKS pathway [18,22–24]. The original pathway comprises two PKS modules on the DepBC enzymes, which are deficient in a functional acyltransferase (AT) domain. Additionally, no evident AT-encoding gene is present within or near the gene cluster. It has been reported that a gene encoding a putative malonyl coenzyme A AT component of the fatty acid synthase complex was determined to be essential for FK228 biosynthesis in *E. coli* cells [24]. Furthermore, a gene (*sfp*) encoding a putative Sfp-type phosphopantetheinyltransferase was also found to be implicated in the heterogeneous expression of FK228 in *E. coli* cells.

To explore the FK228 biosynthesis in EcN, firstly, we constructed a plasmid based on a p15A vector and that contained a dep gene cluster from *C. violaceum* [18] under the control of a BAD promoter. However, no FK228 was detected from the fermentation of *E. coli* cells containing this plasmid because of the lack of a functional AT-encoding gene and a PPTase-encoding gene. As reported that a component of the fatty acid synthase takes responsibility of AT domain function and Sfp-type PPTase is necessary for FK228 synthesis in *E. coli* cells [24], the genes that encoded *fabD1* and Sfp-type PPTase from *C. violaceum* were chosen to follow the regulation of constitutive promoter (Anderson promoters) (S1 Fig) to assist the FK228 biosynthesis in EcN. Considering that the synthesis of FK228 may influence the metabolism of the host cells, an inducible promoter (PBAD promoter, tetracycline inducible promoter, or PfnrS promoter) was applied to regulate the dep modules that were responsible for the most of the reactions involved in FK228 biosynthetic pathways. With codon optimization of all biosynthetic genes and the debugging of promoters, a new plasmid based on a p15A vector and that encoded dep modules A-J under the control of a BAD promoter, and that encoded *fabD1* and Sfp-type PPTase, and other

dep modules K-N under the control of promoter BBa-J23115 was reconstituted, which realized heterogeneous expression of FK228 in *E. coli* cells, especially in EcN (Figs 1 and 3A). As expected, the original FK228 biosynthetic genes from *C. violaceum* did not generate FK228 in EcN (S2 Fig). In addition, the yield of the *E. coli* BL21 that contains FK228 biosynthetic genes with codon optimization was higher than that without codon optimization (S3 Fig).

Reconstitution and generation of FK228-producing EcN strains

As we realized the biosynthesis of FK228 in EcN by use of plasmid 23 (Figs 2 and S4), we reconstructed assistant modules and adjusted promoters based on the plasmid 23 to generate more optimized biosynthetic pathways and corresponding FK228-producing EcN strains with expected high yield (Figs 2 and S4 and S1 Table). A series of optimized EcN strains including EcN-40, EcN (Δ araC)-23, EcN-24, EcN-44, and EcN-25 were determined to heterogeneously express FK228 successfully (Fig 3) with higher yield under aerobic or anaerobic conditions (Fig 4A). The FK228 production of EcN-40 was more than that of others, up to 1.46 mg/L. Subsequently, the yield was 0.714 mg/L (EcN-44), 0.69 mg/L (EcN-24), 0.53 mg/L (EcN (Δ araC)-23), 0.33 mg/L (EcN-23), and 0.001199 mg/L (EcN-25 cultivated under anaerobic condition) at the end of a culture with OD₆₀₀ of 3. What's more, FK228 can be diffused from the EcN cells (Figs 4B and S5), which indicates that FK228 would diffuse to tumor microenvironment when administration of FK228-producing EcN strain. In subsequent investigations, we observed that the FK228-producing EcN strains reached the peak FK228 yield within 24 hours during in vitro fermentation. However, supplementing the inducer at 24 hours further increased FK228 production—this indicates that the peak yield within 24 hours is primarily due to inducer depletion, rather than the death of EcN (S5G Fig). Furthermore, at 6 hours post-induction, a considerable amount of FK228 was already present in the culture medium, reaching approximately half of the peak concentration in each group. Notably, the EcN strains had not yet entered the stationary growth phase at this time, with intact cellular morphology and no significant lysis observed (S5 Fig). These findings confirm that FK228 is released from EcN. Given that FK228 is a small-molecule compound, it is highly plausible that its release occurs via passive diffusion across the bacterial cell membrane. Furthermore, the growth curves of these strains under aerobic conditions with or without inducers have been determined and are presented in S6 Fig. It was observed that the engineered strains grew somewhat more slowly than EcN. Following induced expression, the growth rate of the EcN strains was further restricted, albeit not significantly. Only the OD₆₀₀ of EcN-23 decreased significantly at 4 hours post-induction, with a gradual recovery observed at 7 hours (S6 Fig). This indicates that the expression of FK228 imposes a relatively minor metabolic burden. We also captured photographs of both wild-type EcN and engineered EcN strains (S5H Fig). These images revealed that harboring the FK228 expression plasmid did not exert a significant impact on the morphology of EcN, with the engineered EcN retaining its rod-shaped structure.

The reconstitution and generation of FK228-producing EcN strains were as follows. Since tetracycline (Tet) inducible expression system [25] and the anaerobic-inducible promoter [8] have been reported to control the therapeutic genes expression in EcN, plasmid 24 and 25 were generated based on plasmid 23 by replacing the BAD promoter with Tet promoter and PfnrS promoter, respectively. Recombinant EcN strains were then generated using these plasmids. The FK228 production was analyzed by high-performance liquid chromatography–high resolution mass spectrometry (HPLC-HRMS). HPLC-HRMS spectra demonstrated that the recombinant EcN strains containing plasmid 24 (EcN-24) (Fig 3B) or plasmid 25 (EcN-25) (Fig 3C) could heterogeneously express FK228. The central peak of FK228 from the fermentation was observed compared with the FK228 standard sample. Both plasmid 23 and 24 are under the control of inducible promoter, the production of FK228 was increased with the increase of L-arabinose addition (Fig 4C) or anhydrotetracycline (AHT) addition (Fig 4D) in EcN.

Then we were concerned that the BAD operon within the EcN genome might interfere with the BAD promoter which governs the biosynthesis of FK228. The *araC* gene and the *araCBAD* gene in the genome were knocked out to generate EcN (Δ araC) strain and EcN (Δ araCBAD) strain as new hosts for FK228 biosynthesis. We found that EcN (Δ araC) strain containing plasmid 23 could produce much more FK228 molecules than that of EcN (Δ araCBAD) strain (S7 Fig). Further,




Fig 2. Design and construction of FK228 heterologous expression series plasmids. (A) The construction of the plasmid p15A-cm-pBAD-FK228CODON. (B) The construction of the plasmid 23. (C) The construction of the plasmid 24. (D) The construction of the plasmid 25. (E) The construction of the plasmid 34 and 35. (F) The construction of a series of plasmids in which the *depLNMK* gene has been knocked out. (G) The construction of a series of plasmids in which the *sfp* gene has been replaced. (H) The construction of a series of plasmids in which the constitutive promoter has been replaced, based on the knockout of *depK*.

<https://doi.org/10.1371/journal.pbio.3003657.g002>

we determined the yields of these strains. We found that the yield of EcN (Δ araC) strain containing plasmid 23 was higher than that of EcN-23 (Fig 4A and 4B). EcN (Δ araC)-23 could produce much more FK228 compared with EcN-23 when the same dosage of L-arabinose was used for startup (Fig 4C and 4D). The deletion of araC in the genome may disburden the excessive free araC domain binding to the operator to repress the downstream transcription. Thus, L-arabinose bonded to the araC domain to form complex to regulate FK228 artificial operon.

In addition, restriction modification systems (R-M) in bacterial cells are able to cut the exogenous DNA to protect bacteria themselves. It is rather challenging to transfer plasmids, particularly large ones, into EcN cells. Possibly, the restriction modification systems in EcN impede the survival of exogenous plasmids. Consequently, the relevant genes located in the EcN genome were successively knocked out to produce the recombinant strains depicted in [S8A Fig](#). We found that the knockout of R-M-related genes can slightly increase the plasmid transformation. However, the results of bacterial colonization in tumor ([S8B Fig](#)) showed that the recombinant strains' ability of colonizing in tumors declined compared with the original EcN. Thus, the original EcN is still the preferred host to accommodate FK228 pathways because of the best performance in colonization in tumor.

It is reported that the deduced product of *depM* is an aminotransferase. It is presumably responsible for catalyzing the removal of an amine group from a cysteinyl-S-peptidyl carrier protein (PCP) intermediate in a trans configuration, thereby forming 4-mercaptobutanyl-S-PCP in the initiation module of the FK228 biosynthetic pathway in *C. violaceum* [18]. The *depN* is regarded as a pseudogene; however, it contains regulatory elements upstream of *depA* [22]. The deficiency of *depM* or *depN* could decrease the production of FK228 in *C. violaceum* [22]. On the contrary, the deficiency of the putative genes *depK* or *depL* had no obvious influence on FK228 production in *C. violaceum* [22]. In our study, the *depK-N* genes were reconstructed behind *sfp* gene under the constitutive promoter as the assistant modules for FK228 biosynthesis in




Fig 3. HPLC-HRMS analysis of FK228 production. (A) From top to bottom: HPLC-HRMS analysis was performed on the FK228 standard, followed by the fermentation of the EcN (Δ araC)-23 strain, the fermentation of the EcN-23 strain, the fermentation of the EcN -40 strain. (B) From top to bottom: HPLC-HRMS analysis was performed on the FK228 standard, followed by the fermentation of the EcN-24 strain, the FK228 standard, the fermentation of the EcN-44 strain. (C) From top to bottom: HPLC-HRMS analysis was performed on the FK228 standard, followed by the fermentation of the EcN-25 strain under anaerobic conditions.

<https://doi.org/10.1371/journal.pbio.3003657.g003>




Fig 4. The situation of inducing engineered EcN strains to express FK228 in vitro. (A) Quantification of FK228 production in fermentation of engineered EcN strains ($n=3$). (B) Quantification of FK228 production in supernatant of fermentation of engineered EcN strains ($n=3$). (C, D) The effect of various concentrations of L-arabinose (C) or AHT (D) on FK228 production ($n=3$). (E) Levels of FK228 produced by recombinant EcN strains relative to the EcN-23-1 strain cultivated under aerobic conditions. Only EcN-25 strains are cultivated under anaerobic conditions. The yield at the end of a culture with OD_{600} of 3. Data are mean values of results from duplicate experiments, with error bars indicating standard deviation. Detailed information of strains and plasmids is provided in S1 Table in the supplemental material ($n=3$). The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

<https://doi.org/10.1371/journal.pbio.3003657.g004>

EcN. To investigate the effect of the *depLNMK* modules on FK228 biosynthesis in EcN, the gene *depK-N* was knocked out receptively based on plasmid 23 to generate plasmid 43 ($\Delta depLNMK$), 42 ($\Delta depLNK$), 41 ($\Delta depLK$), 40 ($\Delta depK$), and 39 ($\Delta depL$) and the corresponding recombinant EcN strains in order (S1 Table). As the results showed in Fig 4E, the deletion of *depLNMK* or *depLNK* could decrease the production of FK228 compared with EcN-23-4 strain. However, the deficiency of *depLK* could slightly increase the yield of FK228 compared with EcN-23-4 strain. Hence, the strain EcN-39 ($\Delta depL$ based on

plasmid 23) and EcN-40 ($\Delta depK$ based on plasmid 23) were generated. The FK228 production displayed that the deficiency of *depK* could significantly increase the level of FK228 production in EcN. However, the high level FK228 production may slow down the growth of host to some extent (S6 Fig). The EcN-44 strain biosynthesized the highest level of FK228. Otherwise, the deletion of *depL* had no effect on the production of FK228. Since the deletion of *depK* plays a role in the level of FK228 production, plasmid 44 was constructed based on plasmid 24 by knockout of *depK*. The corresponding recombinant EcN strain containing plasmid 44 (EcN-44) becomes the one with the secondary level of FK228 production (Fig 4A).

The *depR* encodes an LysR-type transcriptional activator, which acts as a pathway regulatory gene governing FK228 biosynthesis in *C. violaceum* [22,26]. The deletion of *depR* abolished FK228 production in *C. violaceum* [22]. However, the deficiency of *depR* had no obvious effect on FK228 production in EcN in our study. The reason may be that a certain homolog of the LysR family of transcriptional regulator in EcN takes the place of *depR* in FK228 biosynthesis.

As mentioned, *fabD1* module takes the place of a functional AT domain involved in FK228 synthesis in *E. coli*. We found that the original *fabD1* had a negative effect on growth of *E. coli*. The optimized-code *fabD1* gene was better. Meanwhile, a gene circuit which *sfp* was followed by *fabD1* was generated (plasmid 62). However, the yield of FK228 of EcN-62 had no obvious improvement compared with that of the former one (Fig 4E). Considering that Sfp-type PPTase plays a role in the FK228 biosynthesis in *E. coli*, a series of Sfp-type PPTase including *sfp* from *C. violaceum*, *MtaA* from *Myxobacterium Stigmatella aurantiaca*, *sfp* from *Bacillus subtilis*, *Pcps* from *Pseudomonas aeruginosa* PAO1, *SpiPcps* from *Pseudomonas sp.* Q71576-was chosen to explore the effect on FK228 yield in EcN. The corresponding plasmids and strains were generated (S1 Table). However, the levels of FK228 production indicated that the optimized-code *sfp* gene from the original *C. violaceum* seemed the best for FK228 biosynthesis in EcN (Fig 4E).

The assistant modules including *fabD1*, *sfp*, and *depLNMK* have been reconstructed for higher FK228 production. We further modified the constitutive promoter that controls the assistant modules based on the *depK* deletion FK228 biosynthetic pathway. A series of Anderson promoters with more strength took the place of the BBa-J23115, which controls the transcription of *sfp-PPTase*, *fabD1*, and *depLNM* (S1 Table). Although these plasmids have been generated successfully, they failed to work in EcN. Thus, these plasmids were transferred into *E. coli* BL21 for FK228 fermentation. However, these plasmids with more strength promoters led to less FK228 compared with the original plasmid 23 in *E. coli* BL21 (S9 Fig). Maybe the strong promoter leading to high transcription of assistant modules disturbs the balance of original growth and metabolism, which resulted in less final products.

The maintenance of the plasmids in bacterial cells without antibiotics selection is a challenge in real-world applications. Antibiotics are not appropriate for clinical applications due to multiple reasons. One significant concern is the horizontal gene transfer of resistance genes, which can lead to the spread of antibiotic resistance among different organisms. Additionally, the use of antibiotics may disrupt the native microbiota, the natural community of microorganisms residing in the body, which can have various consequences on health and physiological balance [27]. Except for antibiotics selection, several mechanisms for stability of plasmid persistence in more complex environments have been developed. The toxin-antitoxin systems have been used for ensuring plasmid maintenance for a certain period of time [28,29]. An the toxin-antitoxin system *Axe-Txe* from *Enterococcus faecium* has been utilized to stabilize plasmids in the absence of antibiotics in vitro and in vivo [27]. In our study, the *Axe-Txe* system and their homologues *yefM-yoeB* from *E. coli* were used for the stability of FK228 plasmids in EcN. However, the plasmids carrying *yefM-yoeB* were failed to be constructed. The plasmids carrying *axe-txe* gene or codon-optimized *axe-txe* gene and the corresponding recombinant strains were constructed successfully. However, the yield of these strains (EcN-34-3, EcN-35-1) showed that the addition of TA system led to a massive reduction of FK228 in EcN. Further investigation should be taken for explanation. Next, we investigated the plasmids maintenance in mouse model (S10 Fig). The results displayed that the codon-optimized AT plasmids led to higher plasmids maintenance compared with the original AT module group. However, the plasmid maintenance rate of the plasmids carrying the AT modules was similar to the one without AT (EcN-23). Considering that the ones with AT modules had low FK228 production in vitro, these strains were not tested in anticancer activities in mouse models.

The transcriptomic differences between engineered EcN strains and EcN before and after induction with L-arabinose

We further test the transcriptional profiles of the engineered FK228-producing strains under the control of L-arabinose to investigate the genetic transcription of FK228 biosynthetic gene cluster in EcN. The transcriptional profile data in Fig 5 revealed that after 24 hours of L-ara induction, a significant amount of *dep* gene cluster mRNA remained in EcN-40, while the residual amounts in EcN-23 and EcN Δ araC-23 were relatively lower. It is hypothesized here that, *depK* might influence the degradation of *dep* gene cluster mRNA or inhibit the utilization of L-ara and gene transcription as a zinc finger protein. Consequently, the yield of FK228 is upregulated after the knockout of *depK*. Meanwhile, the data also indicated that the transcriptional level was markedly attenuated at *depD* and *depE*, suggesting that we could further enhance the synthesis of FK228 by adding an additional promoter at these sites. Furthermore, we observed that, in contrast to the decreasing trend of transcriptional levels that occur with the extension of the gene cluster, the transcriptional levels of the *depI* and *depJ* genes exhibited an upward trend instead. So, we guess that *depI* and *depJ* possess additional transcriptional pathways. This is also in line with the speculation by V. Y. and others [22].

Besides, considering that the biosynthesis of colibactin, as a native secondary metabolite in EcN, may disturb the heterogeneous expression of FK228 in EcN, the genetic transcription of colibactin gene cluster located in EcN genome were




Fig 5. FK228 biosynthetic (*dep*) gene cluster and Colibactin-related transcriptional profiles of engineered EcN strain and EcN. The TPM values of each gene in the colibactin gene cluster in EcN-23 (A), EcN-40 (B), and EcN Δ araC-23 (C) ($n=3$). The TPM values of each gene in the colibactin gene cluster in EcN-23 (D), EcN-40 (E), EcN Δ araC-23 (F), and EcN (G). The TPM values of each regulatory gene of colibactin in EcN-23 (H), EcN-40 (I), EcN Δ araC-23 (J), and EcN (K) ($n=3$). The Transcripts Per Kilobase of exon model per Million mapped reads (TPM). The assay was performed in triplicate and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

<https://doi.org/10.1371/journal.pbio.3003657.g005>

analyzed too. Colibactin, a genotoxic metabolite produced by the majority of intestinal bacteria, is capable of inducing damage to cellular DNA. Simultaneously, it can also trigger prophage induction and potentially affect human diseases [30]. EcN can also express colibactin, but due to its bacterial adhesin FimH mutation, it does not exhibit pathogenicity because of colibactin [31]. However, E. L. and others have recently discovered that colibactin can induce DNA damage in bacteria hundreds of micrometers away [32]. Therefore, we cannot completely disregard the impact of colibactin. According to transcriptional profiles, we have discovered that the expression of colibactin in EcN strains carrying the FK228 expression plasmid, especially after inducible expression, is suppressed. Moreover, the higher the expression level of FK228, the more pronounced the inhibitory effect. We hypothesize that this might be attributed to the competitive action of FK228 (Fig 5D–5G). The genes HtpG, DnaK, UvrY, MarA, AcrA, AcrB, and Fur promote or directly participate in the synthesis of colibactin and are downregulated after the induction of FK228 expression. The CrsA gene inhibits the synthesis of colibactin and is significantly upregulated after the induction of FK228 expression (Fig 5H–5K) [33]. This further demonstrates that the expression of the FK228 gene cluster suppresses the synthesis of colibactin. This can reduce the impact of colibactin on the entire process.

All in all, the deletion of *depK* from the FK228 biosynthetic pathway make great contribution to the heterogeneous expression of FK228 in EcN. The knockout of *araC* from the EcN genome cooperating with BAD promoter also plays a role in high production of FK228. Considering that tumor microenvironment is anaerobic, the anaerobic-inducible promoter has potential to behave better to control FK228 biosynthesis in tumor microenvironment. Thus, the optimized strain with a high yield of FK228 including EcN-40, EcN (Δ araC)-23, EcN-23, EcN-44, and EcN-24, and the EcN-25 strain under the control of low oxygen were chosen for further antitumor investigation.

The activity of FK228-producing EcN strains

Fermentation broth of FK228-producing EcN strain under the control of L-arabinose was tested with mouse breast cancer cells 4T1 and mouse mammary epithelial cells HC11, and their cell viabilities are shown in S11 Fig. The cell viability revealed that the fermentation of broth from the FK228-producing EcN strain (approximately 0.16 μ M FK228) had a significantly inhibition on 4T1 cells compared with that of fermentation of broth from the original EcN strain, and had an even more inhibition than that of positive drugs FK228 (2.5 μ M). Meanwhile, the fermentation of the FK228-producing EcN strain had a similar inhibition on HC11 compared with positive drugs FK228. The fermentation of the original EcN also had a slight inhibition on HC11 cell viability. The IC_{50} values of FK228 on cells were measured and shown in S12 Fig. This result indicated that the FK228-producing EcN had a better inhibition on cell viability of cancer cells. However, the in vivo tumor microenvironment is more complex. Tests in xenograft mouse models are necessary to see if these engineered strains could have anticancer activities.

In vivo anticancer activity of FK228-producing EcN strains

The FK228-producing EcN strains EcN-23, EcN-40, EcN (Δ araC)-23, EcN-24 and EcN-44 were chosen to be investigated for in vivo anticancer activities using a xenograft mouse model due to their high levels of FK228 production. EcN-25 was also selected because continued hypoxia in tumor microenvironment may promote this strain to produce more FK228 for a long time. The FK228 detection results of the FK228-producing EcN strains under the control of L-arabinose are shown in Fig 6. The FK228 signal was detected in the tumor tissues of the FK228-positive group subsequent to either intratumoral injection or intravenous injection. Then, the mice bearing 4T1 tumors were intravenously injected with a suspension of EcN-23, EcN-40, or EcN (Δ araC)-23. The inducer L-arabinose was intraperitoneally injected 48 hours after the administration of these strains. The results showed that FK228 was detected from the tumor tissues 6 hours and 24 hours post administration of inducer. And the highest FK228 was detected from the EcN-40 group, even more than that of FK228-positive group that mice were intraperitoneally injected with FK228 solution. The level of FK228 detection from the EcN-23 group was in the next place. The lowest one was EcN (Δ araC)-23 group. Even if the yield of FK228




Fig 6. Analysis of FK228 detection in tumor tissues or serum derived from the mice bearing 4T1 tumors treated with engineered strains or FK228 standard substance. (A–C) The mice bearing 4T1 tumors were intravenous injected with engineered strains and then intraperitoneal injected with L-arabinose, AHT, or PBS. The tumors were readied for compound detection at 6 or 24 hours post-inducer treatment ($n=4$). For the tumors in the positive group, preparations for compound detection were made at 1 hour following the intraperitoneal injection of the FK228 standard solution, or at 1 or 2 hours post-intratumoural injection of the FK228 standard solution. (D) The levels of FK228 in the serum were detected at 1, 6, and 24 hours after intraperitoneal injection of FK228 or L-arabinose, respectively ($n=5$). The assay was performed in triplicate or quadruplicate and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

<https://doi.org/10.1371/journal.pbio.3003657.g006>

from the fermentation of EcN (Δ araC)-23 was more than that of EcN-23. The results in Fig 6 revealed that the FK228 can be detected in the tumor tissues dissociated from the EcN-24 and EcN-44 groups 6 and 24 hours post administration of inducer anhydrotetracyclin. The FK228 level of EcN-44 was also the highest group 6 hours post administration. The FK228 was also detected from the EcN-25 group 1–4 days post intravenous administration of engineered bacteria. The mice of EcN-25 group were not to be administrated by inducers because the PfnrS promoter senses the oxygen of environment to regulate the downstream pathway. These results indicated that all engineered EcN strains can produce FK228 in tumor environment in situ under the control of a small molecule-inducer. We realized tumor-targeting bacteria EcN heterogeneous express and deliver FK228 in tumor environment after strains colonized in tumors. Additionally, we detected serum FK228 levels at various time points after intraperitoneal injection of either inducers or FK228 itself to investigate its metabolism in the blood of each treatment group. Measurements were taken within 24 hours post-injection. Results showed that FK228 persisted in the blood for 24 hours after injection, with a peak concentration of 0.015 μ g/mL at 6 hours. In contrast, residual FK228 in the blood of the bacterial treatment group remained extremely low throughout the 24-hour period. Instead, FK228 tended to accumulate in tumors in these groups, further highlight the advantages of tumor colonization by these strains, which enables FK228 to be produced and accumulated in tumor tissues (Fig 6D).

Meanwhile, the anticancer activities of these strains were investigated in 4T1 tumor-bearing mouse model. The original EcN was taken as a control. The FK228 group was a positive control. The group without treatment was a blank control. The results are displayed in Figs 7–11. Fig 7 shows the antitumor activities of engineered strains under the control of L-arabinose. The strains EcN-40, EcN-23, and EcN (Δ araC)-23 showed significant inhibition on tumor growth compared with the blank group. Compared with the original EcN, the engineered strains showed much more inhibition of tumor growth. Moreover, the treatment of EcN-23 resulted in a similar inhibition of tumor growth compared with FK228 group. So




Fig 7. The tumor growth rate of mice bearing 4T1 tumors treated with engineered strains and L-arabinose, or EcN, or FK228 standard substance, or PBS. (A) Construction of subcutaneous tumor model and experimental methods for subsequent treatment. (B, C) The mice bearing 4T1 tumors were intravenous injected with engineered strains or wild-type strain at day 0, and then intraperitoneal injected with L-arabinose every two days. The mice in FK228 group were intraperitoneal injected with FK228 standard solution twice or three times a week. The blank group was only intraperitoneal injected with PBS every two days ($n=4$). (D–I) They show the tumor growth rates of the tumors treated by different treatment groups that have been separated out. The assay was performed in quadruplicate and is represented as the mean $\pm$ standard error of the mean (SEM). The statistical significance of differences between two groups was determined using an unpaired two-tailed t test. ns $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

<https://doi.org/10.1371/journal.pbio.3003657.g007>

did EcN-40 group. Figs 8 and 9 displayed the antitumor activities of engineered strains under the control of anhydrotetracycline. The treatment of EcN-24 (Fig 8) and EcN-44 (Fig 9) resulted in the inhibition of tumor growth, which was similar to positive FK228 group. EcN-25 strains including clone 8, clone 11 and clone 16 also showed significant anticancer activities compared with blank group (Fig 10). All EcN-25 strains performed more inhibition on tumor growth beyond the original EcN group. In addition, some of mice in the FK228 treatment group died approaching endpoint. The administration of




Fig 8. The tumor growth rate of mice bearing 4T1 tumors treated with EcN-24 and anhydrotetracycline, or EcN, or FK228 standard substance, or PBS. (A) Establishment of the subcutaneous tumor model and experimental procedures for subsequent treatment. (B, C) The mice bearing 4T1 tumors were intravenous injected with engineered strains or wild-type strain at day 0, and then intraperitoneally injected with anhydrotetracycline every two days ($n=4$). The mice in FK228 group were intraperitoneal injected with FK228 standard solution twice or three times a week. The blank group was only intraperitoneal injected with PBS every two days. (D–G) They show the tumor growth rates of the tumors treated by different treatment groups that have been separated out. The assay was performed in quadruplicate and is represented as the mean $\pm$ standard error of the mean (SEM). The statistical significance of differences between two groups was determined using an unpaired two-tailed t test. ns $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

<https://doi.org/10.1371/journal.pbio.3003657.g008>

engineered EcN strains resulted in less mortality of mice in experiments. The reason may be that the tumor-targeting EcN producing and delivering FK228 in tumor microenvironment could reduce the side effects of FK228. The tumor colonization of engineered EcN ensured the concentration and accumulation of FK228 in tumor microenvironment, which reduced the side effects of FK228 compared with direct intravenous injection of FK228. At the endpoint, the bacterial colonization in the tumors has been determined and shown in [S13 Fig](#). Most engineered strain groups have CFU counts in tumors that are similar to or lower than those in the EcN group. Only EcN-23 has colonized tumors to a greater extent compared to EcN. Besides, there is a possibility that the mice will die within the FK228 treatment group throughout the approximately three-week FK228 treatment course ([S14 Fig](#)). In contrast, the mice in the engineered EcN groups will survive during the roughly three-week treatment period. The results suggested that FK228 has side effects in cancer treatment.

In addition, we selected EcN-23, EcN-40, EcN-24, EcN-44, and EcN-25, which exhibited relatively good performance, and re-conducted animal experiments to evaluate their anti-tumor activity. In this experiment, the injection concentration of FK228 was lowered, and the injection frequency was reduced. Fortunately, no mouse deaths occurred in the FK228 group during the treatment period. However, as anticipated, the therapeutic efficacy of the FK228-positive group decreased,




Fig 9. The tumor growth rate of mice bearing 4T1 tumors treated with EcN-44 and anhydrotetracycline, or EcN, or FK228 standard substance, or PBS. (A) Establishment of the subcutaneous tumor model and experimental procedures for subsequent treatment. (B, C) The mice bearing 4T1 tumors were intravenously injected with engineered strains or wild type stain at day 0, and then intraperitoneally injected with anhydrotetracycline every two days. The mice in FK228 group were intraperitoneally injected with FK228 standard solution twice or three times a week. The blank group was only intraperitoneally injected with PBS every two days ($n=4$). (D–G) They show the tumor growth rates of the tumors treated by different treatment groups that have been separated out. The assay was performed in quadruplicate and is represented as the mean $\pm$ standard error of the mean (SEM). The statistical significance of differences between two groups was determined using an unpaired two-tailed t test. ns $p>0.05$, * $p<0.05$, ** $p<0.01$, *** $p<0.001$. The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

<https://doi.org/10.1371/journal.pbio.3003657.g009>

reaching a level comparable to that of the EcN group. The EcN-44, EcN-23, and EcN-24 groups showed relatively superior tumor growth inhibition effects compared with the EcN group (Fig 11). At the end of the experiment, the mice's tumors were dissected and photographed (S15 and S16 Figs). In general, these FK228-producing strains demonstrate potential for anti-tumor activity.

The proteomic differences of tumors after treatment with different treatment groups

We further investigate the proteome of tumor tissues that are treated with FK228-producing EcN strains. In the screening of significantly differential proteins, with the criteria of fold change (FC) > 1.5 times (up-regulated more than 1.5 times or down-regulated less than 0.67 times) and P value < 0.05 (T test or other), the number of up-regulated and down-regulated proteins between the comparison groups was obtained (Fig 12A and 12B).

Perform Gene Ontology (GO) terms on differentially expressed genes to classify their functions (Fig 12C). The results of the GO analysis show that engineered EcN strains can initiate and enhance immune responses through antigen




Fig 10. The tumor growth rate of mice bearing 4T1 tumors treated with EcN-25, or EcN, or FK228 standard substance, or PBS. (A) Establishment of the subcutaneous tumor model and experimental procedures for subsequent treatment. (B, C) The mice bearing 4T1 tumors were intravenously injected with engineered strains or wild type stains at day 0. The mice in FK228 group were intraperitoneal injected with FK228 standard solution twice or three times a week ($n=4$). (D-I) They show the tumor growth rates of the tumors treated by different treatment groups that have been separated out. The assay was performed in quadruplicate and is represented as the mean $\pm$ standard error of the mean (SEM). The statistical significance of differences between two groups was determined using an unpaired two-tailed t test. ns $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

<https://doi.org/10.1371/journal.pbio.3003657.g010>

presentation, complement activation, response to interleukin, and other means, thereby exerting a killing effect on tumor cells. Additionally, they can induce apoptosis and ferroptosis in cells via oxidative stress [34,35]. Simultaneously, it can also inhibit angiogenesis and tumor development. However, the inflammatory reaction caused during this process may also affect cancer treatment and development. We can also observe that the direct use of FK228 can down-regulate




Fig 11. The tumor growth rate of mice bearing 4T1 tumors treated with engineered strains and inducer, or EcN, or FK228 standard substance, or PBS. (A) Establishment of the subcutaneous tumor model and experimental procedures for subsequent treatment. (B, C) The mice bearing 4T1 tumors were intravenous injected with engineered strains or wild-type strain at day 0, and then intraperitoneal injected with L-arabinose every two days. The mice in FK228 group were intraperitoneal injected with FK228 standard solution twice or three times a week. The blank group was only intraperitoneal injected with PBS every two days ($n=5$). (D–K) They show the tumor growth rates of the tumors treated by different treatment groups that have been separated out. The assay was performed in quadruplicate and is represented as the mean $\pm$ standard error of the mean (SEM). The statistical significance of differences between two groups was determined using an unpaired two-tailed t test. ns $p>0.05$, * $p<0.05$, ** $p<0.01$, *** $p<0.001$. The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

<https://doi.org/10.1371/journal.pbio.3003657.g011>

centromere-associated proteins to inhibit cell proliferation and promote cell apoptosis by regulating ubiquitination modification, especially the expression of cullin family proteins [36]. Nevertheless, the direct use of FK228 does have an impact on cardiomyocytes and myocardial tissue [37], which does not occur in the EcN treatment group (S17 Fig). The GO analysis of engineered EcN strains in comparison with the EcN group and the FK228 group reveals that: in contrast to EcN, engineered EcN strains possess not only stronger immunostimulatory and oxidative stress-stimulating effects but also the capabilities of modulating ubiquitination modification and promoting histone acetyltransferase activity. Compared




Fig 12. Histogram of protein quantification differences. Overlap of the Identified Quantities among different groups (A), and groups for difference comparison (B). Significantly changing in abundance: Differentially expressed proteins that meet the screening fold and p-value criteria. Upregulated: Differentially expressed proteins with upregulated expression. Downregulated: Differentially expressed proteins with downregulated expression. (C) A volcano plot is drawn for the proteins in the comparison group based on two factors: Fold change and P value (*T* test). Among them, the significantly down-regulated proteins are marked in blue ($FC < 0.67$ and $p < 0.05$), the significantly up-regulated proteins are marked in red ($FC > 1.5$ and $p < 0.05$), and the proteins with no difference are in gray ($n = 5$).

<https://doi.org/10.1371/journal.pbio.3003657.g012>

with FK228, engineered EcN strains can exert additional immunostimulatory and oxidative stress-stimulating effects and promote the function of p53, thereby achieving a better cancer treatment outcome (S17 Fig). Therefore, engineered EcN strains not only combine the tumor treatment capabilities of EcN and FK228 but also surpass them in many aspects, while reducing the side effects such as cardiotoxicity produced by FK228 during the treatment process.

The volcano plot displayed the abnormally expressed genes in the two datasets. We selected the top 10 proteins with the most significant up-regulation and down-regulation in each group compared with the Blank group for the study (Fig 12C and S2 Table). We found that the tumor suppressor genes *Pthr1*, *Rpl36a-ps1*, *Rps25*, as well as immunoglobulin-related genes including *Ighg3*, *Igkv9-120*, *Igkc*, *Ighm*, *Ighg2b*, and *Iglv2*, showed a significant increase in expression in all EcN groups or engineered EcN strains treatment groups [38–41], while there was no significant change in the FK228 group. The oncogenes *Ftn1*, *Fbn1*, *Gcsh*, *Ptma*, *Mecp2*, *Fxn*, *Ctsh*, *Got2*, *Csnk1g2*, *Lrp6*, *Prss23*, *Mylk*, and *Adamtsl4* exhibited a significant decrease in expression in all EcN groups or Engineered EcN strains treatment groups [42–54], with

no obvious change in the FK228 group. This indicates that EcN or engineered EcN strains, rather than FK228, exert an anti-cancer effect by regulating these proteins.

The genes *Ppp3cb*, *Phf11*, *Sepsecs*, and *Uck1* are among the most significantly up-regulated tumor suppressor genes in the FK228 group [55–58]. The genes *Gpr84*, *Faah*, *Mettl2*, *Taf12*, *Cd163*, and *Cyth1* are the most significantly down-regulated oncogenes in the FK228 group [59–64]. Among them, *Ppp3cb* contributes to Herceptin resistance, and the combination of *Cd163* and *GPR84* antagonists with anti-PD-1 antibodies has enhanced the anti-tumor response. These existing research results suggest to us that these engineered EcN strains may achieve a more excellent therapeutic effect in combination with related drugs [55,63,65].

The significantly differentially expressed proteins in the direct comparison between the engineered EcN strains group and both the EcN group and the FK228 group showed that compared with the EcN treatment group, the oncogene and drug resistance-related genes *Anxa3*, *Kif14*, and *Ecd* in the engineered EcN strains group were downregulated [66–68]. In comparison with the FK228 treatment group, the tumor suppressor genes *Siglec12*, *Stfa2*, and immunoglobulin-related genes in the engineered EcN strains group were upregulated [69,70]. Meanwhile, compared with the other two groups, the oncogene and drug resistance-related genes *B2m*, *Pf4*, and *Rps25* in the engineered EcN strains group all exhibited downregulated expression [41,71,72], while the tumor suppressor genes *Csnk1g2*, *Hfe*, *Col4a1*, *Ptma*, *Fbn1*, *Taf1a*, *Ahsa2*, *Adap2*, *Zfp871*, and *Dhx34* all showed upregulated expression (Fig 12C and S2 Table) [43,45,50,73–79]. This indicates that the engineered EcN strains may inhibit the development of cancer by more effectively regulating these genes. These existing research results also provide some inspiration for our subsequent combination drug therapy.

Conclusion

In this paper, we propose an *in vivo* therapeutic approach that utilizes engineered, tumor-colonizing probiotics for the expression of anti-cancer compounds. We have shown that EcN is capable of successfully and controllably expressing FK228 both *in vitro* and *in vivo* through the reconstructed biosynthetic pathway of FK228. Six engineered EcN strains, owing to their tumor-restricted colonization features, can nimbly and directly release FK228 inside the tumor under diverse induction conditions based on varying circumstances, thus attaining the effect of tumor-targeted therapy.

During the modification procedures of gene clusters and the chassis bacteria, we decreased the quantity of inducer necessary for inducing the engineered EcN strains, elevated their FK228 expression levels and improved plasmid stability. Moreover, we found that knocking out the *depK* gene, which encodes a zinc finger protein, could remarkably enhance the expression of FK228 in EcN. Correspondingly, the fermentation yield of FK228 (up to 1.5 mg/L) by the engineered strain attained a level that was 27 times higher than that of the EcN-23 strain, and the residual amount of FK228 in the tumor within 6 hours was as high as 1.5 µg/g, leading to a relatively remarkable tumor treatment effect. In the remaining groups, the tumor inhibitory effects of EcN-23 strain, EcN-25 strain, EcN-40 strain, and EcN-44 strain were almost identical to that of FK228, while the tumor inhibitory effect of EcN-24 strain was even better than FK228. Moreover, the toxicity of all these strains was lower than that of FK228. Notably, although the expression level of FK228 in the tumor of the EcN-25 strain was extremely low, it still achieved a favorable therapeutic effect, probably due to the continuous drug release.

The utilization of bacteria offers an auxiliary organism that is capable of facilitating tumor-specific targeted drug delivery and overcoming the hurdle of FK228 having difficulty penetrating the necrotic and hypoxic areas of solid tumors. Additionally, it provides inherent inflammatory characteristics that play a part in strengthening the anti-tumor response. The initiation of the inflammatory response and the consequent immune reaction it instigates can work in synergy with FK228 to enhance the therapeutic effectiveness [80,81]. Transcriptomic findings also demonstrated that EcN harboring the optimized gene cluster of FK228, particularly after induction, could strikingly suppress the expression of colibactin in EcN. Meanwhile, the engineered EcN strains were able to considerably mitigate the cardiotoxicity and associated side effects brought about by FK228, averting or markedly diminishing deaths caused by drug toxicity.

To further clarify the *in vivo* mechanism of action of engineered EcN strains, proteomic analyses were carried out on tumor tissues prior to and following treatment with engineered EcN strains, EcN, and FK228. Engineered EcN strains exhibit the combined advantages of EcN and FK228 in tumor treatment. They may potentially promote the transformation of cold tumors into hot tumors by triggering and enhancing the body's immune responses, as well as regulate cancer-related genes by influencing post-translational modifications such as ubiquitination and acetylation, thereby exerting anti-cancer effects. Moreover, the regulation of most relevant proteins is more conspicuous when compared with that of EcN and FK228.

There are still areas in this study that require improvement and further exploration. In bacterial cancer therapy, tumor-colonizing bacteria form the core of this modality. Common chassis strains include EcN, attenuated *Salmonella*, and *Listeria*. However, natural tumor-targeting bacteria show limited therapeutic efficacy, requiring artificial modification to gain anti-tumor activity. This study engineers EcN to express anti-tumor therapeutic molecules, as wild-type EcN has weak inherent anti-tumor activity. Plasmids carrying therapeutic gene clusters are modified to enhance engineered strains' efficacy. FDA clinical trial results indicate some engineered candidates failed due to insufficient therapeutic effects, necessitating further efforts to develop high-efficacy strains for disease treatment.

Secondly, the reliance on intravenous administration of engineered strains requiring exogenous inducers for FK228 biosynthesis presents a potential clinical limitation. Although we mitigated this by demonstrating the effectiveness of anaerobic promoters, eliminating the need for added inducers, achieving precise spatiotemporal control *in vivo* remains a critical challenge. Alternative induction strategies, such as oral inducers or safe light-controlled, reactive oxygen species-controlled, and electronically-controlled systems [82,83], are under development to enhance clinical translatability.

Thirdly, plasmid loss may result in the failure of efficient FK228 production, which in turn compromises its therapeutic efficacy. Consequently, during the development of engineered strains in the future, priority should be given to maintaining the stability of exogenous therapeutic DNA molecules. Moreover, in the practical transition towards clinical applications, it is imperative to explore appropriate strategies for sustaining the genetic stability of the strains.

Furthermore, although previous research has indicated that EcN exhibits a relatively high colonization efficiency in tumor metastases, with low bacterial concentrations in the blood and other organs and a tendency to disappear after a certain period without triggering systemic reactions [84,85], the methods for eliminating the bacteria after treatment still need to be considered in subsequent studies.

Additionally, harnessing programmed bacterial cell lysis could enhance FK228 diffusion and efficacy [86,87]. Significant knowledge gaps persist regarding the therapeutic performance of engineered EcN across different species, tumor types, and contexts like oral administration or combination therapies. Further *in vivo* and *in vitro* studies are essential to comprehensively understand the strain's applicability and limitations.

Although direct FK228 injection may seem simpler, its efficacy against solid tumors is suboptimal at clinically relevant doses, often causing toxicity or insufficient tumor inhibition in animal models. In contrast, our strategy of bacterial tumor colonization followed by localized FK228 synthesis enhances tumor-targeting, potentially concentrating therapeutic effects, reducing systemic side effects, and improving drug utilization compared to direct administration.

In conclusion, the research outcomes concerning our engineered EcN strains that heterologously express FK228 offer novel insights and effective tools for the exploration of probiotic strains in tumor treatment. They establish a solid foundation for the engineering bacteria which are capable of producing small-molecule anticancer drugs and engaged in bacteria-assisted tumor-targeted therapy, paving the way for future advancements in this field.

Materials and methods

Strains, culture conditions, and plasmids

[S1](#) and [S3 Tables](#) detail the bacterial strains, plasmids, and primers employed in this study, with gene synthesis and codon optimization performed by Sangon Biotech. The *Escherichia coli* (*E. coli*) strains were cultivated in Luria-Bertani (LB) medium at 37°C within a thermostatic oscillator operating at 950 rpm. The liquid LB medium comprised 5g/L yeast

extract, 10g/L pancreatin, and 0.1% or 1% sodium chloride. Solid LB medium was formulated by supplementing liquid LB medium with 1.2% agar. The sodium chloride was sourced from Genview, antibiotics, and the remaining components were provided by Thermo Fisher Invitrogen.

Construction of plasmid and recombinant strains

The tool plasmid pSC101-BAD-ccdA-Rha-Gbaa-tet was introduced into EcN through electroporation. Subsequently, the gene OxyR and genes associated with the arabinose operon were substituted with spectinomycin and chloramphenicol resistance genes flanked by lox66 and lox71 sites via recombination. After screening for the correct single clones using colony PCR, the plasmid pSC101-BAD-ccdA-Rha-Gbaa-tet was removed by culturing at 37°C. Similarly, the plasmid RK2-BAD-Cre-SacB was transformed into the modified EcN. Upon induction of Cre enzyme expression, recombination was triggered by the recognition of the two lox sites, leading to the deletion of the resistance selection marker between them. The single clones successfully removing the selection marker were identified by colony PCR. Subsequently, the obtained correct strain was serially subcultured three times in a sucrose-containing medium, streaked in three sectors on LB plates, and ultimately, the target gene-knocked-out ECN without plasmid was obtained by double-plate streaking.

The original core genes and the codon-optimized core genes required for FK228 biosynthesis were partially synthesized by Genewiz, Sangon Biotech, and Beijing Genomics institution. The primers for FK228 synthesis and the synthesized oligonucleotides are listed in [S3](#) and [S4 Tables](#), respectively. We employed the engineered *E. coli* strain GB05dir-gyrA462 to conduct multipiece DNA assembly, thereby constructing plasmids 01-p15A-cm-FK228CODON-F12-3-neoccdB, 02-BR322-cmccdB-FK228codon-F47, and 03-BR322-cmccdB-FK228codon-F811. Subsequently, we digested them with the SnaI enzyme and assembled them into the plasmid p15A-cm-pBAD-FK228CODON using the ExoCET technology. After digesting the plasmid p15A-cm-pBAD-FK228CODON with Scal and AatII, the digested products were combined with the PCR product kam-oriT through linear plus linear homologous recombination (LLHR) to form the plasmid 23-p15A-km-pBAD-FK228. Other plasmids were constructed based on plasmid 23 by linear plus circular homologous recombination (LCHR), LLHR, and RedEx methods. amp-ccdB, cm-ccdB, and spect-ccdB served as a selection-counterselection marker in this process. The accurate single colonies were identified through restriction enzyme digestion verification and then subjected to sequencing. EcN and engineered EcN can transform with constructed plasmid DNA by means of conjugation with the *Escherichia coli* donor strain WM3064.

Fermentation and high-performance liquid chromatography-mass spectrometry analysis of the metabolites derived from Engineered EcN

Engineered EcN strains were inoculated from a plate into 50 mL LB in 250 mL flasks and incubated with shaking at 200 rpm at 30°C for about 3 hours. When it grew to the logarithmic growth phase, the corresponding inducer was added. XAD16 macroporous adsorption resin was added at 72 hours of cultivation, and extraction was carried out with methanol at the end of a culture with OD₆₀₀ of 3 (96 hours). With the exception of the EcN strain harboring the fnrs promoter, which was subjected to anaerobic fermentation throughout the entire process, all other strains were cultured under aerobic fermentation conditions. The extract was filtered through a 0.22 µm filter and then subjected to HPLC–MS analysis.

High-resolution mass spectrometry analysis was performed on high-Resolution Q-TOF mass spectrometry (impactHD). The mobile phases consisted of H₂O with 0.1% (v/v) formic acid (solvent A) and acetonitrile (ACN) with 0.1% (v/v) formic acid (solvent B). The ion source was ESI and the flow rate was 0.3 ml/min. The gradient solvent conditions were as follows: maintain at 5% B for 3 min, increase from 5% B to 95% within 15 min, maintain at 95% B for 4 min, and then maintain 5% B for 3 min. The quantification of compounds was carried out on the UPLC-Triple Quadrupole Mass Spectrometer System (Triple Quad 5500+ QTRAP+X-5). The gradient solvent conditions were: maintain at 5% B for 1 min, increase from 5% B to 98% within 4 min, maintain at 98% B for 2 min, and then maintain 5% B for 3 min. The remaining conditions were the same as those for high-resolution mass spectrometry analysis.

Cell culture and mouse model

The cells we used were mouse mammary epithelial cells HC11 (purchased from DINGGUO CHANGSHENG) and mouse breast cancer cells 4T1 (Lab stock). The reagents used included Gibco's RPMI 1640 medium, Pen-Strep antibiotic, Trypsin-EDTA (0.25%), Fetal Bovine Serum (FBS), and PBS from Procell. The RPMI 1640 used was supplemented with 1% Pen-Strep antibiotic and 10% FBS. All cell lines were cultured and maintained in a humidified incubator at 37°C with 5% CO₂.

Cell viability assay: Firstly, cells were trypsinized to obtain cell suspensions, with 1×10^4 cells being carefully seeded into each well of a 96-well plate. The plate was then incubated overnight to allow cells to adhere firmly. Meanwhile, the fermentation broth was filtered under sterile conditions and subsequently introduced into the 96-well plate containing the adhered cells. FK228 served as the positive control throughout the experiment. Following a 24-hour incubation period, the culture medium was gently aspirated, and the cells were rinsed 2–3 times using PBS. Next, a CCK-8 solution was added. After an incubation of 3–4 hours, the absorbance values were measured to calculate the cell survival rate.

All animal studies were conducted in accordance with the guidelines of the Ethics Committee and the IACUC protocols of the School of Life Sciences, Shandong University. All animal experiments were reviewed and approved by the IACUC of Shandong University (Approval No.: SYDWLL-2022-023). The experimental animals employed in this study were 8-week-old female BALB/c mice procured from Shandong Jinan Pengyue Animal Co.. Immediately upon receipt, the mice were housed in a controlled environment with a precisely regulated 12-hour light/dark cycle and furnished with sterile bedding, feed, and water for a period of one week to allow them to acclimate and reach a stable physiological state. Subsequently, a mouse allograft tumor model was established by subcutaneously injecting 5×10^5 4T1 murine breast cancer cells into the right forelimb of each mouse. When the tumors had grown to a volume ranging from 300 to 600 mm³, 100 µL of EcN strains culture (with an OD₆₀₀ = 0.2, approximately 1.2×10^7 CFU) (S16 Fig) containing was administered to the mice via tail vein injection. Forty-eight hours after the injection of the engineered bacteria, the 100 µL inducer, PBS, or 0.3 mg/mL FK228 was intraperitoneally injected, and then the injection was repeated every 48 hours [88,89]. Tumor volume = length × width²/2. Upon completion of the experiment, the mice were anesthetized with isoflurane prior to euthanasia via cervical dislocation.

Antitumor activity and FK228 detection in tumor

The day of injecting the bacterial solution was designated as day zero. The body weight of the mice as well as the length and width of the tumors were measured every 48 hours. On the last day of the experiment, the tumors were removed, washed with PBS, dried with sterile paper to remove surface moisture, and then weighed. After homogenizing the tumors, they were diluted and spread for counting colony-forming units (CFU). For the detection of FK228 in the tumors, the tumors were removed 6 hours and 24 hours after injecting the inducer (for the intratumoral injection and intraperitoneal injection FK228 groups, the tumors were removed 1 hour and 2 hours after injection). After homogenizing the tumors, extraction was carried out. The extract was used for FK228 quantification by the UPLC-Triple Quadrupole Mass Spectrometer System. When the tumor volume reached 1,500 cubic millimeters, the mice were considered dead and euthanized. Proteomic sequencing assays were subsequently performed on the tumor tissues of the animals. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [90] partner repository with the dataset identifier PXD073783.

Supporting information

S1 Fig. The necessity of the genes *fabD1* and *sfp* for the heterologous expression of FK228 in *Escherichia coli*.

And the Anderson promoters that can be used to construct the plasmids that encoded the *fabD1* and *sfp*-type PPtase from *Chromobacterium violaceum* for assisting the FK228 biosynthesis in EcN.

(TIFF)

S2 Fig. The MS analysis of FK228 detection from the fermentation of engineered EcN clones. The FK228 had not been detected from the fermentation of the EcN that contained the original FK228 biosynthetic genes from *Chromobacterium violaceum* (clones 15, 18, and 20). The FK228 had been detected from the fermentation of the EcN that contains the codon optimized FK228 gene cluster (clone 1,426).

(TIFF)

S3 Fig. The MS analysis of FK228 detection from the fermentation of engineered *Escherichia coli* BL21 clones. (A)

The FK228 had been detected from the fermentation of the *E. coli* BL21 that contains codon optimized FK228 gene cluster (clone 1–4 and 10) and the *E. coli* BL21 that contain the original FK228 gene clusters from *Chromobacterium violaceum* (clone 15 and 18). **(B)** The FK228 yield of the *E. coli* BL21 that contains FK228 biosynthetic genes with codon optimization was higher than that without codon optimization ($n=3$). The assay was performed in triplicate and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S4 Fig. Restriction analysis of constructed plasmids involved in anticancer therapy. (A) XmnI restriction analysis of plasmid 23, 24, and 25. **(B)** BamHI restriction analysis of plasmid 40 and 44. Correct clones are indicated with red check mark.

(TIFF)

S5 Fig. Quantification of FK228 production and the CFU counting of fermentation culture. (A–C) Data from Batch 1 experiments (24 h–96 h): **(A)** Quantification of FK228 production in supernatant of fermentation and precipitation of engineered EcN strains ($n=3$). **(B)** The proportion of FK228 that diffused into the culture medium to the total FK228 produced ($n=3$). **(C)** Analysis of viable cell count during fermentation of engineered EcN strains ($n=3$). **(D–F)** Data from Batch 2 experiments (0 h–24 h): Quantification of FK228 production in the fermentation supernatant and pellet of engineered EcN strains, as well as the OD600 and CFU of the bacteria within 24 hours ($n=3$). **(G)** FK228 production of EcN-23 at 24 h, 48 h, and 48 h with an additional inducer supplementation at 24 h ($n=3$). **(H)** Scanning electron microscopy (SEM) images of EcN strains at different time points during fermentation. The magnification of all SEM images is 20,000 $\times$. The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S6 Fig. Growth curve of engineered EcN strains (A) and the induced EcN strains (B). The engineered EcN strains were uniformly diluted to an OD600 of 0.1 and then cultured in LB medium with 1% NaCl. The culture was continuously shaken at 750 rpm at 37°C. The OD600 was measured every 5 min for a total of 24 hours to draw the growth curve ($n=5$). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S7 Fig. Analysis of FK228 detection in the fermentation of EcN-23, EcN (Δ araC)-23 and EcN (Δ araCBAD)-23. The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S8 Fig. The tumor colonization of restriction-modification enzymes knockout strains. (A) Genes related to restriction-modification enzymes and the corresponding EcN strains with gene knockouts. **(B)** The colonization status of EcN strains with gene knockouts in tumors. Data are mean values of results from duplicate experiments, with error bars indicating standard deviation. The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S9 Fig. The promoter adjustment for partial FK228-producing plasmids and the FK228 production from the fermentation of the corresponding engineered *Escherichia coli* BL21 strains. (A) The Anderson promoters that were used to construct these plasmids. (B) The FK228 yield of *E. coli* BL21 containing these plasmids. The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S10 Fig. The plasmid maintenance of AT series strains. The mice bearing 4T1 tumors were intravenously injected with the suspension of AT series strains EcN-34, EcN-35, EcN-DR004-34, EcN-DR004-35, and CK strain EcN-23 respectively. The blank group was intravenous administration of PBS. The mice in EcN-23 were intragastric administration of kanamycin solution daily. The mice in the AT series strains group were not intragastric administration of antibiotics ($n=4$). Data are mean values of results from duplicate experiments, with error bars indicating standard deviation. The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S11 Fig. Cell viability. Cell viability of 4T1 (A) cells and HC11 (B) cells incubated with the fermentation supernatant of engineered EcN strain (approximately 0.16 μ M FK228), EcN wild type strain or FK228 standard solution (2.5 μ M). Data are mean values of results from duplicate experiments, with error bars indicating standard deviation. The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S12 Fig. The proliferative effects of FK228 on mouse breast cancer cells and mouse mammary epithelial cells. The CCK-8 kit was employed to determine the cell inhibitory effect on 4T1 (A) cells and HC11 (B) cells subsequent to their incubation with FK228. Data are mean values of results from duplicate experiments, with error bars indicating standard deviation. The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S13 Fig. The colonization of engineered EcN strains and EcN in tumors. (A) The colonization of engineered EcN strains and EcN in tumors 15 days after injection. (B) The colonization of EcN-25 in tumors 20 days after injection ($n=3$). Data are mean values of results from duplicate experiments, with error bars indicating standard deviation. The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S14 Fig. Survival curves of mice bearing 4T1 tumors treated with engineered EcN strains, or EcN, FK228, or PBS. (A) supporting information for Fig 7. (B) Supporting information for Fig 8. (C) Supporting information for Fig 9. (D) Supporting information for Fig 10 ($n=4$). Data are mean values of results from duplicate experiments, with error bars indicating standard deviation. The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S15 Fig. Images of isolated tumors. Supporting information for Fig 11.

(TIFF)

S16 Fig. The colony-forming units (CFU) of EcN strains to be used for tail vein injection. The EcN strains to be used for tail vein injection were serially diluted, and the diluted samples were spread on LB agar plates. The colonies were counted to calculate the CFU ($n=3$). Data are mean values of results from duplicate experiments, with error bars indicating standard deviation. The assay was performed in triplicate (biological replicates) and is represented as the mean $\pm$ standard error of the mean (SEM). The underlying data can be found in <https://figshare.com/s/340f560874499f66444e>.

(TIFF)

S17 Fig. GO analysis of differential proteins in tumor tissues among different treatment groups.

(DOCX)

S1 Table. Bacterial strains and plasmids used in this study.

(DOCX)

S2 Table. Top 10 Significant Differential Proteins of Tumors after Different Treatments.

(DOCX)

S3 Table. Primers used in this study.

(DOCX)

S4 Table. The codon-optimized core genes for FK228 synthesis.

(DOCX)

S1 Raw images. Original Gel Image for S4 Fig.

(DOCX)

Acknowledgments

We are grateful to Dr. Chaoyi Song for his assistance in plasmid construction. We thank Guannan Lin, Zhifeng Li, Jing Zhu, and Jingyao Qu of the Core Facilities for Life and Environmental Sciences, State Key Laboratory of Microbial Technology of Shandong University for UPLC-Triple Quadrupole Mass Spectrometer System and High-Resolution Q-TOF mass spectrometry analysis. Thanks to Sen Wang, Haiyan Yu, Xiaomin Zhao, and Yuyu Guo from Core Facilities for Life and Environmental Sciences at the SKLMT (State Key Laboratory of Microbial Technology, Shandong University) for the assistance provided in scanning electron microscopy/focused ion beam microscopy sample preparation and imaging. We are grateful to Sangon Biotech for conducting transcriptomic analysis and proteomic analyses.

Author contributions

Conceptualization: Youming Zhang, Tianyu Jiang.

Funding acquisition: Hailong Wang, Youming Zhang, Tianyu Jiang.

Investigation: Chenghao Ma, Geng Li, Tao Sun, Ximi Tang, Tong Qiu, Jingwen Song, Tianyu Jiang.

Methodology: Chenghao Ma, Geng Li, Tao Sun, Ximi Tang, Tong Qiu, Jingwen Song, Tianyu Jiang.

Supervision: Hailong Wang, Youming Zhang.

Visualization: Chenghao Ma, Tianyu Jiang.

Writing – original draft: Chenghao Ma, Tianyu Jiang.

Writing – review & editing: Hailong Wang, Youming Zhang.

References

- Gurbatri CR, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies. *Science*. 2022;378(6622):858–64. <https://doi.org/10.1126/science.add9667> PMID: 36423303
- Zhou Y, Han Y. Engineered bacteria as drug delivery vehicles: principles and prospects. *Eng Microbiol*. 2022;2(3):100034. <https://doi.org/10.1016/j.engmic.2022.100034> PMID: 39629029
- Murali SK, Mansell TJ. Next generation probiotics: engineering live biotherapeutics. *Biotechnol Adv*. 2024;72:108336. <https://doi.org/10.1016/j.biotechadv.2024.108336> PMID: 38432422
- Redenti A, Im J, Redenti B, Li F, Rouanne M, Sheng Z, et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. *Nature*. 2024;635(8038):453–61. <https://doi.org/10.1038/s41586-024-08033-4> PMID: 39415001
- He X, Guo J, Bai Y, Sun H, Yang J. Salmonella-based therapeutic strategies: improving tumor microenvironment and bringing new hope for cancer immunotherapy. *Med Oncol*. 2024;42(1):27. <https://doi.org/10.1007/s12032-024-02578-0> PMID: 39666238
- Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. *Nat Med*. 2019;25(7):1057–63. <https://doi.org/10.1038/s41591-019-0498-z> PMID: 31270504
- Gurbatri CR, Lia I, Vincent R, Coker C, Castro S, Treuting PM, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. *Sci Transl Med*. 2020;12(530):eaax0876. <https://doi.org/10.1126/scitranslmed.aax0876> PMID: 32051224
- Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, Gallant CW, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. *Nat Commun*. 2020;11(1):2739. <https://doi.org/10.1038/s41467-020-16602-0> PMID: 32483165
- Canale FP, Basso C, Antonini G, Perotti M, Li N, Sokolovska A, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. *Nature*. 2021;598(7882):662–6. <https://doi.org/10.1038/s41586-021-04003-2> PMID: 34616044
- Li R, Helbig L, Fu J, Bian X, Herrmann J, Baumann M, et al. Expressing cytotoxic compounds in *Escherichia coli* Nissle 1917 for tumor-targeting therapy. *Res Microbiol*. 2019;170(2):74–9. <https://doi.org/10.1016/j.resmic.2018.11.001> PMID: 30447257
- Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Tumor-specific colonization, tissue distribution, and gene induction by probiotic *Escherichia coli* Nissle 1917 in live mice. *Int J Med Microbiol*. 2007;297(3):151–62. <https://doi.org/10.1016/j.ijmm.2007.01.008> PMID: 17448724
- He L, Yang H, Tang J, Liu Z, Chen Y, Lu B, et al. Intestinal probiotics *E. coli* Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. *J Biol Eng*. 2019;13:58. <https://doi.org/10.1186/s13036-019-0189-9> PMID: 31297149
- Zhang Y, Ji W, He L, Chen Y, Ding X, Sun Y, et al. *E. coli* nissle 1917-derived minicells for targeted delivery of chemotherapeutic drug to hypoxic regions for cancer therapy. *Theranostics*. 2018;8(6):1690–705. <https://doi.org/10.7150/thno.21575> PMID: 29556350
- Xie S, Zhao L, Song X, Tang M, Mo C, Li X. Doxorubicin-conjugated *Escherichia coli* Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. *J Control Release*. 2017;268:390–9. <https://doi.org/10.1016/j.jconrel.2017.10.041> PMID: 29101053
- Gao Q, Deng S, Jiang T. Recent developments in the identification and biosynthesis of antitumor drugs derived from microorganisms. *Eng Microbiol*. 2022;2(4):100047. <https://doi.org/10.1016/j.engmic.2022.100047> PMID: 39628704
- Pojani E, Barlocco D. Romidepsin (FK228), a histone deacetylase inhibitor and its analogues in cancer chemotherapy. *Curr Med Chem*. 2021;28(7):1290–303. <https://doi.org/10.2174/0929867327666200203113926> PMID: 32013816
- Hirokawa Y, Arnold M, Nakajima H, Zalcborg J, Maruta H. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. *Cancer Biol Ther*. 2005;4(9):956–60. <https://doi.org/10.4161/cbt.4.9.1911> PMID: 16082189
- Cheng Y-Q, Yang M, Matter AM. Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in *Chromobacterium violaceum* No. 968. *Appl Environ Microbiol*. 2007;73(11):3460–9. <https://doi.org/10.1128/AEM.01751-06> PMID: 17400765
- Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by *Chromobacterium violaceum* No. 968. III. Antitumor activities on experimental tumors in mice. *J Antibiot (Tokyo)*. 1994;47(3):315–23. <https://doi.org/10.7164/antibiotics.47.315> PMID: 8175484
- Gong K, Wang M, Duan Q, Li G, Yong D, Ren C, et al. High-yield production of FK228 and new derivatives in a *Burkholderia* chassis. *Metab Eng*. 2023;75:131–42. <https://doi.org/10.1016/j.ymben.2022.12.002> PMID: 36528227
- Liu X, Xie F, Doughty LB, Wang Q, Zhang L, Liu X, et al. Genomics-guided discovery of a new and significantly better source of anticancer natural drug FK228. *Synth Syst Biotechnol*. 2018;3(4):268–74. <https://doi.org/10.1016/j.synbio.2018.10.011> PMID: 30417143
- Potharla VY, Wesener SR, Cheng Y-Q. New insights into the genetic organization of the FK228 biosynthetic gene cluster in *Chromobacterium violaceum* no. 968. *Appl Environ Microbiol*. 2011;77(4):1508–11. <https://doi.org/10.1128/AEM.01512-10> PMID: 21183645
- Wang C, Wesener SR, Zhang H, Cheng Y-Q. An FAD-dependent pyridine nucleotide-disulfide oxidoreductase is involved in disulfide bond formation in FK228 anticancer depsipeptide. *Chem Biol*. 2009;16(6):585–93. <https://doi.org/10.1016/j.chembiol.2009.05.005> PMID: 19549597
- Wesener SR, Potharla VY, Cheng Y-Q. Reconstitution of the FK228 biosynthetic pathway reveals cross talk between modular polyketide synthases and fatty acid synthase. *Appl Environ Microbiol*. 2011;77(4):1501–7. <https://doi.org/10.1128/AEM.01513-10> PMID: 21183648
- Loessner H, Leschner S, Endmann A, Westphal K, Wolf K, Kochruebe K, et al. Drug-inducible remote control of gene expression by probiotic *Escherichia coli* Nissle 1917 in intestine, tumor and gall bladder of mice. *Microbes Infect*. 2009;11(14–15):1097–105. <https://doi.org/10.1016/j.micinf.2009.08.002> PMID: 19665575

26. Qiao Y, Tong T, Xue J, Lin W, Deng Z, Cheng Y-Q, et al. Mechanistic studies of DepR in regulating FK228 biosynthesis in *Chromobacterium violaceum* no. 968. PLoS One. 2018;13(4):e0196173. <https://doi.org/10.1371/journal.pone.0196173> PMID: 29672625
27. Fedorec AJH, Ozdemir T, Doshi A, Ho Y-K, Rosa L, Rutter J, et al. Two new plasmid post-segregational killing mechanisms for the implementation of synthetic gene networks in *Escherichia coli*. iScience. 2019;14:323–34. <https://doi.org/10.1016/j.isci.2019.03.019> PMID: 30954530
28. Grady R, Hayes F. Axe-Txe, a broad-spectrum proteic toxin-antitoxin system specified by a multidrug-resistant, clinical isolate of *Enterococcus faecium*. Mol Microbiol. 2003;47(5):1419–32. <https://doi.org/10.1046/j.1365-2958.2003.03387.x> PMID: 12603745
29. Lin J, Guo Y, Yao J, Tang K, Wang X. Applications of toxin-antitoxin systems in synthetic biology. Eng Microbiol. 2023;3(2):100069. <https://doi.org/10.1016/j.engmic.2023.100069> PMID: 39629251
30. Silpe JE, Wong JWH, Owen SV, Baym M, Balskus EP. The bacterial toxin colibactin triggers prophage induction. Nature. 2022;603(7900):315–20. <https://doi.org/10.1038/s41586-022-04444-3> PMID: 35197633
31. Jans M, Kolata M, Blancke G, D'Hondt A, Gräf C, Ciers M, et al. Colibactin-driven colon cancer requires adhesin-mediated epithelial binding. Nature. 2024;635(8038):472–80. <https://doi.org/10.1038/s41586-024-08135-z> PMID: 39506107
32. Lowry E, Mitchell A. Colibactin-induced damage in bacteria is cell contact independent. mBio. 2025;16(1):e0187524. <https://doi.org/10.1128/mbio.01875-24> PMID: 39576109
33. Addington E, Sandalli S, Roe AJ. Current understandings of colibactin regulation. Microbiology (Reading). 2024;170(2):001427. <https://doi.org/10.1099/mic.0.001427> PMID: 38314762
34. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1–40. <https://doi.org/10.1016/j.cbi.2005.12.009> PMID: 16430879
35. Fan X, Liu F, Wang X, Wang Y, Chen Y, Shi C, et al. LncFASA promotes cancer ferroptosis via modulating PRDX1 phase separation. Sci China Life Sci. 2024;67(3):488–503. <https://doi.org/10.1007/s11427-023-2425-2> PMID: 37955780
36. Xu T, Ma Q, Li Y, Yu Q, Pan P, Zheng Y, et al. A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer. Signal Transduct Target Ther. 2022;7(1):354. <https://doi.org/10.1038/s41392-022-01182-w> PMID: 36253371
37. Ververis K, Rodd AL, Tang MM, El-Osta A, Karagiannis TC. Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cell Mol Life Sci. 2011;68(24):4101–14. <https://doi.org/10.1007/s00018-011-0727-1> PMID: 21584806
38. Gao C, Chen J, Bai J, Zhang H, Tao Y, Wu S, et al. High glucose-upregulated PD-L1 expression through RAS signaling-driven downregulation of PTRH1 leads to suppression of T cell cytotoxic function in tumor environment. J Transl Med. 2023;21(1):461. <https://doi.org/10.1186/s12967-023-04302-4> PMID: 37434177
39. Cao X, Khitun A, Luo Y, Na Z, Phoodokmai T, Sappakhaw K, et al. Alt-RPL36 downregulates the PI3K-AKT-mTOR signaling pathway by interacting with TMEM24. Nat Commun. 2021;12(1):508. <https://doi.org/10.1038/s41467-020-20841-6> PMID: 33479206
40. Hsu H-M, Chu C-M, Chang Y-J, Yu J-C, Chen C-T, Jian C-E, et al. Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis. Sci Rep. 2019;9(1):4484. <https://doi.org/10.1038/s41598-019-40826-w> PMID: 30872752
41. Zhang X, Wang W, Wang H, Wang M-H, Xu W, Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene. 2013;32(22):2782–91. <https://doi.org/10.1038/onc.2012.289> PMID: 22777350
42. Zhang X-X, Luo J-H, Wu L-Q. FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer. Front Genet. 2022;13:913659. <https://doi.org/10.3389/fgene.2022.913659> PMID: 36035176
43. Shen NN, Lin JH, Liu PP. EBF1 promotes the sensitivity of cervical cancer cells to cisplatin via activating FBN1 transcription. Mol Biol (Mosk). 2023;57(3):503–4. <https://doi.org/10.31857/s0026898423030102> PMID: 37326054
44. Adamus A, Müller P, Nissen B, Kasten A, Timm S, Bauwe H, et al. GCSH antisense regulation determines breast cancer cells' viability. Sci Rep. 2018;8(1). <https://doi.org/10.1038/s41598-018-33677-4>
45. Yang L, Sun H, Liu X, Chen J, Tian Z, Xu J, et al. Circular RNA hsa_circ_0004277 contributes to malignant phenotype of colorectal cancer by sponging miR-512-5p to upregulate the expression of PTMA. J Cell Physiol. 2020;10.1002/jcp.29484. <https://doi.org/10.1002/jcp.29484> PMID: 31960446
46. Wang Y, Zhang Y, Wang F, Li T, Song X, Shi H, et al. Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer. Sci Rep. 2022;12(1):18518. <https://doi.org/10.1038/s41598-022-21328-8> PMID: 36323715
47. Du J, Zhou Y, Li Y, Xia J, Chen Y, Chen S, et al. Identification of Frataxin as a regulator of ferroptosis. Redox Biol. 2020;32:101483. <https://doi.org/10.1016/j.redox.2020.101483> PMID: 32169822
48. Chen Q, Qu S, Liang Z, Liu Y, Chen H, Ma S, et al. Cathepsin H knockdown reverses radioresistance of hepatocellular carcinoma via metabolic switch followed by apoptosis. Int J Mol Sci. 2023;24(6):5257. <https://doi.org/10.3390/ijms24065257> PMID: 36982347
49. Kerk SA, Garcia-Bermudez J, Birsoy K, Sherman MH, Shah YM, Lyssiotis CA. Spotlight on GOT2 in cancer metabolism. Onco Targets Ther. 2023;16:695–702. <https://doi.org/10.2147/OTT.S382161> PMID: 37635751
50. Li R, Zhou Q, Liu G, Zhu F, Liu Z, Bo H, et al. CSNK1G2-AS1 promotes metastasis, colony formation and serves as a biomarker in testicular germ cell tumor cells. J Cancer. 2023;14(15):2771–83. <https://doi.org/10.7150/jca.85640> PMID: 37781070

51. Li L, Zhao L, Yang J, Zhou L. Multifaceted effects of LRP6 in cancer: exploring tumor development, immune modulation and targeted therapies. *Med Oncol*. 2024;41(7):180. <https://doi.org/10.1007/s12032-024-02399-1> PMID: 38898247
52. Chan H-S, Chang S-J, Wang T-Y, Ko H-J, Lin Y-C, Lin K-T, et al. Serine protease PRSS23 is upregulated by estrogen receptor α and associated with proliferation of breast cancer cells. *PLoS One*. 2012;7(1):e30397. <https://doi.org/10.1371/journal.pone.0030397> PMID: 22291950
53. Mirzaei M, Sheikholeslami SA, Jalili A, Bereimipour A, Sharbati S, Kaveh V, et al. Investigating the molecular mechanisms of Tamoxifen on the EMT pathway among patients with breast cancer. *J Med Life*. 2022;15(6):835–44. <https://doi.org/10.25122/jml-2022-0085> PMID: 35928368
54. Zhao Z, Zhang K-N, Chai R-C, Wang K-Y, Huang R-Y, Li G-Z, et al. ADAMTSL4, a secreted glycoprotein, is a novel immune-related biomarker for primary glioblastoma multiforme. *Dis Markers*. 2019;2019:1802620. <https://doi.org/10.1155/2019/1802620> PMID: 30728876
55. Luo L, Zhang Z, Qiu N, Ling L, Jia X, Song Y, et al. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. *Nat Commun*. 2021;12(1):2699. <https://doi.org/10.1038/s41467-021-23052-9> PMID: 33976188
56. Yu H, Jiang Y, Liu L, Shan W, Chu X, Yang Z, et al. Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer. *Oncotarget*. 2017;8(8):13099–115. <https://doi.org/10.18632/oncotarget.14402> PMID: 28055972
57. Yang H, Wang X, Blanco-Gómez A, He L, García-Sancha N, Corchado-Cobos R, et al. A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice. *EBioMedicine*. 2024;106:105260. <https://doi.org/10.1016/j.ebiom.2024.105260> PMID: 39067134
58. Zhang H, Huang H, Feng X, Song H, Zhang Z, Shen A, et al. Deubiquitinase USP28 inhibits ubiquitin ligase KLHL2-mediated uridine-cytidine kinase 1 degradation and confers sensitivity to 5'-azacytidine-resistant human leukemia cells. *Theranostics*. 2020;10(3):1046–59. <https://doi.org/10.7150/thno.36503> PMID: 31938050
59. Zhang X, Wang Y, Supekar S, Cao X, Zhou J, Dang J, et al. Pro-phagocytic function and structural basis of GPR84 signaling. *Nat Commun*. 2023;14(1):5706. <https://doi.org/10.1038/s41467-023-41201-0> PMID: 37709767
60. Tripathy M, Bui A, Henderson J, Sun J, Woods CR, Somani S, et al. FAAH inhibition ameliorates breast cancer in a murine model. *Oncotarget*. 2023;14:910–8. <https://doi.org/10.18632/oncotarget.28534> PMID: 37921652
61. Yuan W, Zhang R, Lyu H, Xiao S, Guo D, Zhang Q, et al. Dysregulation of tRNA methylation in cancer: mechanisms and targeting therapeutic strategies. *Cell Death Discov*. 2024;10(1):327. <https://doi.org/10.1038/s41420-024-02097-x> PMID: 39019857
62. Guo X, Chen J, Fang A, Ji Q, Chen F, Zhou X, et al. Elevated TAF12 expression predicts poor prognosis in glioma patients: evidence from bioinformatic and immunohistochemical analyses. *Biomolecules*. 2022;12(12):1847. <https://doi.org/10.3390/biom12121847> PMID: 36551275
63. Liu Z, Gao Z, Li B, Li J, Ou Y, Yu X, et al. Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression. *Oncoimmunology*. 2022;11(1):2085432. <https://doi.org/10.1080/2162402X.2022.2085432> PMID: 35712121
64. Ren W-X, Guo H, Lin S-Y, Chen S-Y, Long Y-Y, Xu L-Y, et al. Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199. *Acta Pharmacol Sin*. 2024;45(1):180–92. <https://doi.org/10.1038/s41401-023-01142-2> PMID: 37644132
65. Qin G, Liu S, Liu J, Hu H, Yang L, Zhao Q, et al. Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells. *Signal Transduct Target Ther*. 2023;8(1):164. <https://doi.org/10.1038/s41392-023-01388-6> PMID: 37105980
66. Liu C, Li N, Liu G, Feng X. Annexin A3 and cancer. *Oncol Lett*. 2021;22(6):834. <https://doi.org/10.3892/ol.2021.13095> PMID: 34712358
67. Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, et al. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. *Neoplasia*. 2014;16(3):247–56, 256.e2. <https://doi.org/10.1016/j.neo.2014.03.008> PMID: 24784001
68. Xu S-H, Zhu S, Wang Y, Huang J-Z, Chen M, Wu Q-X, et al. ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation. *Cell Death Dis*. 2018;9(5):479. <https://doi.org/10.1038/s41419-018-0525-x> PMID: 29706618
69. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. *Nat Rev Immunol*. 2007;7(4):255–66. <https://doi.org/10.1038/nri2056> PMID: 17380156
70. Breznik B, Mitrović A, T Lah T, Kos J. Cystatins in cancer progression: more than just cathepsin inhibitors. *Biochimie*. 2019;166:233–50. <https://doi.org/10.1016/j.biochi.2019.05.002> PMID: 31071357
71. Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. *Front Immunol*. 2022;13:844866. <https://doi.org/10.3389/fimmu.2022.844866> PMID: 35296095
72. Pilatova K, Greplova K, Demlova R, Bencsikova B, Klement GL, Zdravilova-Dubská L. Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology. *J Hematol Oncol*. 2013;6:42. <https://doi.org/10.1186/1756-8722-6-42> PMID: 23800319
73. Dong P, Cai Z, Li B, Zhu Y, Chan AKY, Chiang MWL, et al. HFE promotes mitotic cell division through recruitment of cytokinetic abscission machinery in hepatocellular carcinoma. *Oncogene*. 2022;41(36):4185–99. <https://doi.org/10.1038/s41388-022-02419-2> PMID: 35882980
74. Guo J, Ma X, Liu D, Wang F, Xia J, Zhang B, et al. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis. *Drug Resist Updat*. 2024;76:101116. <https://doi.org/10.1016/j.drug.2024.101116> PMID: 38968684
75. Wang M, Liao J, Wang J, Qi M, Wang K, Wu W. TAF1A and ZBTB41 serve as novel key genes in cervical cancer identified by integrated approaches. *Cancer Gene Ther*. 2021;28(12):1298–311. <https://doi.org/10.1038/s41417-020-00278-1> PMID: 33311601

76. Han SW, Ahn JY, Lee S, Noh YS, Jung HC, Lee MH, et al. Gene expression network analysis of lymph node involvement in colon cancer identifies AHS2, CDK10, and CWC22 as possible prognostic markers. *Sci Rep*. 2020;10(1):7170. <https://doi.org/10.1038/s41598-020-63806-x> PMID: [32345988](https://pubmed.ncbi.nlm.nih.gov/32345988/)
77. Qiang Y, Wang X, Ding J, Wang Z, Li B, Ji H, et al. Elevated Expression of ADAP2 is Associated With Aggressive Behavior of Human Clear-Cell Renal Cell Carcinoma and Poor Patient Survival. *Clin Genitourin Cancer*. 2023;21(2):e78–91. <https://doi.org/10.1016/j.clgc.2022.08.003> PMID: [36127253](https://pubmed.ncbi.nlm.nih.gov/36127253/)
78. Yan W, Scoumanne A, Jung Y-S, Xu E, Zhang J, Zhang Y, et al. Mice deficient in poly(C)-binding protein 4 are susceptible to spontaneous tumors through increased expression of ZFP871 that targets p53 for degradation. *Genes Dev*. 2016;30(5):522–34. <https://doi.org/10.1101/gad.271890.115> PMID: [26915821](https://pubmed.ncbi.nlm.nih.gov/26915821/)
79. Liu N, Wang Q, Zhu P, He G, Li Z, Chen T, et al. DHX34 as a promising biomarker for prognosis, immunotherapy and chemotherapy in pan-cancer: a comprehensive analysis and experimental validation. *J Cancer*. 2024;15(20):6594–615. <https://doi.org/10.7150/jca.102230> PMID: [39668816](https://pubmed.ncbi.nlm.nih.gov/39668816/)
80. Shen L, Orillion A, Pili R. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. *Epigenomics*. 2016;8(3):415–28. <https://doi.org/10.2217/epi.15.118> PMID: [26950532](https://pubmed.ncbi.nlm.nih.gov/26950532/)
81. Losson H, Schneckeburger M, Dicato M, Diederich M. Natural Compound Histone Deacetylase Inhibitors (HDACi): synergy with inflammatory signaling pathway modulators and clinical applications in cancer. *Molecules*. 2016;21(11):1608. <https://doi.org/10.3390/molecules21111608> PMID: [27886118](https://pubmed.ncbi.nlm.nih.gov/27886118/)
82. Huang J, Xue S, Teixeira AP, Fussenegger M. A mediator-free sonogenetic switch for therapeutic protein expression in mammalian cells. *Nucleic Acids Res*. 2025;53(6):gkaf191. <https://doi.org/10.1093/nar/gkaf191> PMID: [40114374](https://pubmed.ncbi.nlm.nih.gov/40114374/)
83. VanArsdale E, Pitzer J, Wang S, Stephens K, Chen C-Y, Payne GF, et al. Electrostatic signal transmission and propagation in coculture to guide production of a small molecule, tyrosine. *ACS Synth Biol*. 2022;11(2):877–87. <https://doi.org/10.1021/acssynbio.1c00522> PMID: [35113532](https://pubmed.ncbi.nlm.nih.gov/35113532/)
84. Gurbatri CR, Radford GA, Vrbanc L, Im J, Thomas EM, Coker C, et al. Engineering tumor-colonizing *E. coli* Nissle 1917 for detection and treatment of colorectal neoplasia. *Nat Commun*. 2024;15(1):646. <https://doi.org/10.1038/s41467-024-44776-4> PMID: [38245513](https://pubmed.ncbi.nlm.nih.gov/38245513/)
85. Chen H, Lei P, Ji H, Yang Q, Peng B, Ma J, et al. Advances in *Escherichia coli* Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies. *Mater Today Bio*. 2023;18:100543. <https://doi.org/10.1016/j.mtbio.2023.100543> PMID: [36647536](https://pubmed.ncbi.nlm.nih.gov/36647536/)
86. Saeidi N, Wong CK, Lo T-M, Nguyen HX, Ling H, Leong SSJ, et al. Engineering microbes to sense and eradicate *Pseudomonas aeruginosa*, a human pathogen. *Mol Syst Biol*. 2011;7:521. <https://doi.org/10.1038/msb.2011.55> PMID: [21847113](https://pubmed.ncbi.nlm.nih.gov/21847113/)
87. Hwang IY, Koh E, Wong A, March JC, Bentley WE, Lee YS, et al. Engineered probiotic *Escherichia coli* can eliminate and prevent *Pseudomonas aeruginosa* gut infection in animal models. *Nat Commun*. 2017;8:15028. <https://doi.org/10.1038/ncomms15028> PMID: [28398304](https://pubmed.ncbi.nlm.nih.gov/28398304/)
88. Jiang T, Yang X, Li G, Zhao X, Sun T, Müller R, et al. Bacteria-based live vehicle for in vivo bioluminescence imaging. *Anal Chem*. 2021;93(47):15687–95. <https://doi.org/10.1021/acs.analchem.1c03568> PMID: [34783525](https://pubmed.ncbi.nlm.nih.gov/34783525/)
89. Ma C, Liu J, Liu H, Zhao X, Li G, Zhang Y, et al. Tumor-targeting bioluminescent bacteria for in vivo imaging. *Eng Microbiol*. 2025;5(3):100224. <https://doi.org/10.1016/j.engmic.2025.100224>
90. Perez-Riverol Y, Bandla C, Kundu DJ, Kamatchinathan S, Bai J, Hewapathirana S, et al. The PRIDE database at 20 years: 2025 update. *Nucleic Acids Res*. 2025;53(D1):D543–53. <https://doi.org/10.1093/nar/gkae1011> PMID: [39494541](https://pubmed.ncbi.nlm.nih.gov/39494541/)